Bellevue Life Sciences Acquisition Corp.
Status: Closed Deal
U=S+W+R
W=S@11.5
R=S/10
| IPO Proceeds, $M | $69.00M |
|---|---|
| IPO Date | Feb 10, 2023 |
| CEO | Kuk Hyoun Hwang |
| Left Lead | Chardan |
| IPO Cash in Trust | 101.8% |
| SPAC Tenor | 9 + 6 + 6 + 3 |
| IPO Sector | Healthcare â–¶ |
| IPO Geography | Global |
| Target Company | OSR Holdings |
| Deal Announced | Nov 16, 2023 |
| Deal Size, $M | TBD |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Feb 13, 2025 |
| Amendment Vote | Nov 12, 2024 |
| Closing Date | Feb 14, 2025 |
Formerly BLAC
OSRH
OSRHW
| Price | $1.62 |
|---|---|
| Last closing price | $1.50 |
| H/L, today | $1.47 / $1.75 |
| Volume, today | 468,104 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.